Biopharmaceutical
Research
Development
Antiviral
Commercialization
Unitedstates
Acquisition
Immunomedics
M&A Advisory
Lazard
Full Credential Description
Gilead Sciences. United States. Announced Date 13/09/2020. Closed Date 23/10/2020. Deal value: $21000m. Gilead Sciences to acquire Immunomedics. Industry: Gilead Sciences is a biopharmaceutical company that focuses on the research, development, and commercialization of antiviral drugs and treatments.